Charged Alpha logo
CHARGED ALPHA
Stock Analysis
Stock Library / PACS
PACS Healthcare Latest YouTube: Q1 2026 Published 2026-05-12

PACS Group, Inc.

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest earnings video

PACS Stock: EPS Beats by 19% — Q1 2026 Earnings Analysis

Published 2026-05-12

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q1 2026
2026-05-12
Podcast available
Yes
Current price
$44.25
+0.50 (+1.14%)
Trailing / Forward P/E
25.88x
Forward: 16.31x
Market cap / Volume
Volume:
Revenue / Earnings Growth
9.1%
Earnings: 51.6%
Margins
7.7% op
Gross: 17.3% · Net: 4.8%
Balance sheet
0.91x current
Debt / Equity: 305.3
52-week range / Beta
$7.50 - $49.49
Beta: -0.08
Analyst target
$59.20
Upside: 33.8%
Cash / shareholder return
5.40% FCF yield
Dividend yield: —

Company context

Industry: Medical Care Facilities
Country: United States
Employees:
Price to book: 6.71x
Return on equity: 27.9%
PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. It also provides senior care and independent living facilities. The company engages in the acquisition, ownership, and leasing of health care-related properties. PACS Group, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

Price chart

Market context for PACS

Competitive view

PACS vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

PACS Group, Inc. latest YouTube video thumbnail YouTube
PACS Group, Inc.
PACS
Latest video
Q1 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.
Intuitive Surgical latest YouTube video thumbnail YouTube
Intuitive Surgical
ISRG
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Johnson & Johnson latest YouTube video thumbnail YouTube
Johnson & Johnson
JNJ
Latest video
Q2 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
PACS
$7.01B
PACS Group, Inc.
ISRG
$135.72B
Intuitive Surgical
JNJ
$651.25B
Johnson & Johnson
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
PACS
25.9x
PACS Group, Inc.
ISRG
43.5x
Intuitive Surgical
JNJ
31.4x
Johnson & Johnson
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
PACS
16.3x
PACS Group, Inc.
ISRG
31.4x
Intuitive Surgical
JNJ
22.0x
Johnson & Johnson
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
PACS
9.1%
PACS Group, Inc.
ISRG
18.5%
Intuitive Surgical
JNJ
6.6%
Johnson & Johnson
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
PACS
51.6%
PACS Group, Inc.
ISRG
26.5%
Intuitive Surgical
JNJ
-0.9%
Johnson & Johnson
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
PACS
7.7%
PACS Group, Inc.
ISRG
33.6%
Intuitive Surgical
JNJ
29.2%
Johnson & Johnson
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
PACS
17.3%
PACS Group, Inc.
ISRG
66.7%
Intuitive Surgical
JNJ
68.1%
Johnson & Johnson
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
PACS
4.8%
PACS Group, Inc.
ISRG
28.4%
Intuitive Surgical
JNJ
21.5%
Johnson & Johnson
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
PACS
27.9%
PACS Group, Inc.
ISRG
17.4%
Intuitive Surgical
JNJ
25.7%
Johnson & Johnson
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
PACS
5.4%
PACS Group, Inc.
ISRG
1.9%
Intuitive Surgical
JNJ
2.6%
Johnson & Johnson
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
PACS
305.26x
PACS Group, Inc.
ISRG
Intuitive Surgical
JNJ
57.71x
Johnson & Johnson
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
PACS
0.91x
PACS Group, Inc.
ISRG
4.96x
Intuitive Surgical
JNJ
1.09x
Johnson & Johnson
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
PACS
-0.08
PACS Group, Inc.
ISRG
1.46
Intuitive Surgical
JNJ
0.23
Johnson & Johnson
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
PACS
PACS Group, Inc.
ISRG
Intuitive Surgical
JNJ
2.0%
Johnson & Johnson
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
PACS
33.8%
PACS Group, Inc.
ISRG
26.2%
Intuitive Surgical
JNJ
0.8%
Johnson & Johnson

Episode timeline

Episode archive for PACS

Each row is one earnings episode with every verified platform link available.

Q1 2026
Episode live
2026-05-12
Published youtube podcast complete
PACS Stock: EPS Beats by 19% — Q1 2026 Earnings Analysis
Quarterly earnings-analysis entry for PACS Group, Inc.. Use the links on the right to open the video or podcast episode.